Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates

European Journal of Pharmacology

Volumn 723, Issue 1, 2014, Pages 108-115

  Amano, Yuichiro ^a   Shimada, Mitsuyuki ^a   Miura, Shotaro ^a   Adachi, Ryutaro ^a   Tozawa, Ryuichi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Cholestyramine; Farnesoid X receptor antagonist; Hepatic lipid content; Hepatic mRNA expression; High density lipoprotein cholesterol; Low density lipoprotein cholesterol

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; COMPOUND T3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOLIPOPROTEIN A1 GENE; ARTICLE; CHOLESTEROL 7ALPHA HYDROXYLASE GENE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; DYSLIPIDEMIA; FECES LEVEL; FEMALE; GENE EXPRESSION; LIPID METABOLISM; LIVER METABOLISM; MACACA FASCICULARIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TISSUE WATER; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

CHOLESTYRAMINE; FARNESOID X RECEPTOR ANTAGONIST; HEPATIC LIPID CONTENT; HEPATIC MRNA EXPRESSION; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; LOW-DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMALS; APOLIPOPROTEIN A-I; BENZOATES; BILE ACIDS AND SALTS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLESTYRAMINE RESIN; DIET, HIGH-FAT; FECES; FEMALE; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPIDEMIAS; INDAZOLES; LIPID METABOLISM; LIPID REGULATING AGENTS; LIVER; MACACA FASCICULARIS; MALE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, LDL; RNA, MESSENGER;

EID: 84891511757     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.10.048     Document Type: Article

References (19)

1. M. Ananthanarayanan, N. Balasubramanian, M. Makishima, D.J. Mangelsdorf, and F.J. Suchy Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor J. Biol. Chem. 276 2001 28857 28865
2. B. Cariou, and B. Staels FXR: a promising target for the metabolic syndrome? Trends Pharmacol. Sci. 28 2007 236 243
3. T. Claudel, E. Sturm, H. Duez, I.P. Torra, A. Sirvent, V. Kosykh, J.C. Fruchart, J. Dallongeville, D.W. Hum, F. Kuipers, and B. Staels Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element J. Clin. Invest. 109 2002 961 971
4. P.W. Connelly The role of hepatic lipase in lipoprotein metabolism Clin. Chim. Acta 286 1999 243 255
5. H.B. Hartman, K. Lai, and M.J. Evans Loss of small heterodimer partner expression in the liver protects against dyslipidemia J. Lipid Res. 50 2009 193 203
6. H. Huang, Y. Yu, Z. Gao, Y. Zhang, C. Li, X. Xu, H. Jin, W. Yan, R. Ma, J. Zhu, X. Shen, H. Jiang, L. Chen, and J. Li Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists J. Med. Chem. 55 2012 7037 7053
7. T. Inagaki, M. Choi, A. Moschetta, L. Peng, C.L. Cummins, J.G. McDonald, G. Luo, S.A. Jones, B. Goodwin, J.A. Richardson, R.D. Gerard, J.J. Repa, D.J. Mangelsdorf, and S.A. Kliewer Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis Cell Metab. 2 2005 217 225
8. R. Krishna, M.S. Anderson, A.J. Bergman, B. Jin, M. Fallon, J. Cote, K. Rosko, C. Chavez-Eng, R. Lutz, D.M. Bloomfield, M. Gutierrez, J. Doherty, F. Bieberdorf, J. Chodakewitz, K.M. Gottesdiener, and J.A. Wagner Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914
9. Y. Ma, Y. Huang, L. Yan, M. Gao, and D. Liu Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance Pharm. Res. 30 2013 1447 1457
10. L. Malerod, M. Sporstol, L.K. Juvet, S.A. Mousavi, T. Gjoen, T. Berg, N. Roos, and W. Eskild Bile acids reduce SR-BI expression in hepatocytes by a pathway involving FXR/RXR, SHP, and LRH-1 Biochem. Biophys. Res. Commun. 336 2005 1096 1105
11. S.K. Moestrup, and L.B. Nielsen The role of the kidney in lipid metabolism Curr. Opin. Lipidol. 16 2005 301 306
12. D.J. Rader A new feature on the cholesterol-lowering landscape Nat. Med. 7 2001 1282 1284
13. D. Rhainds, and L. Brissette The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders Int. J. Biochem. Cell Biol. 36 2004 39 77
14. C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, and F.J. Gonzalez Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 2000 731 744
15. A. Sirvent, A.J. Verhoeven, H. Jansen, V. Kosykh, R.J. Darteil, D.W. Hum, J.C. Fruchart, and B. Staels Farnesoid X receptor represses hepatic lipase gene expression J. Lipid Res. 45 2004 2110 2115
16. M. Sorci-Thomas, M.M. Prack, N. Dashti, F. Johnson, L.L. Rudel, and D.L. Williams Apolipoprotein (apo) A-I production and mRNA abundance explain plasma apoA-I and high density lipoprotein differences between two nonhuman primate species with high and low susceptibilities to diet-induced hypercholesterolemia J. Biol. Chem. 263 1988 5183 5189
17. N.J. Stone, S. Bilek, and S. Rosenbaum Recent national cholesterol education program adult treatment panel III update: adjustments and options Am. J. Cardiol. 96 2005 53E 59E
18. F.J. Suchy, and M. Ananthanarayanan Bile salt excretory pump: biology and pathobiology J. Pediatr. Gastroenterol. Nutr. 43 Suppl 1 2006 S10 S16
19. Y. Zhang, H.R. Kast-Woelbern, and P.A. Edwards Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation J. Biol. Chem. 278 2003 104 110